Format

Send to

Choose Destination
See comment in PubMed Commons below
Case Rep Oncol. 2011 Jan 15;4(1):16-8. doi: 10.1159/000323804.

Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer.

Author information

  • 1Department of Oncology, University Hospital Zürich, Zürich, Switzerland.

Abstract

We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.

KEYWORDS:

Chromophobe renal cell cancer; Liver metastases; Sorafenib; Sunitinib; Temsirolimus

PMID:
21526001
PMCID:
PMC3082484
DOI:
10.1159/000323804
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Support Center